Adherence to treatment in osteoporosis influence on efficiency;Observance et persistance: Impact sur l'efficience des traitements de l'ostéoporose

Revue Medicale Suisse

Volumn 1, Issue 35, 2005, Pages 2278-2281

  Reginster, Jean Yves ^a   Rabenda, Véronique ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; RISEDRONIC ACID;

BONE DENSITY; DRUG EFFICACY; HUMAN; OSTEOPOROSIS; PATIENT COMPLIANCE; REVIEW; TREATMENT OUTCOME; ARTICLE; CHEMISTRY; DRUG ADMINISTRATION;

CHEMISTRY, PHARMACEUTICAL; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; HUMANS; OSTEOPOROSIS; PATIENT COMPLIANCE;

EID: 32944466830     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Sung JC, Nichol MB, Venturini F, et al. Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care 1998;4:421-30.
2. Giuffrida A, Torgerson DJ. Should we pay the patient? Review of financial incentives to enhance patient compliance. BMJ 1997;315:703-7.
3. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: A cross-national study. JAMA 1998;279:458-62.
4. Reginster JY, Lecart MP. Treatment of osteoporosis with bisphosphonates - Do compliance and persistence matter? Business Briefing: Long-term Healthcare, 2004;65-8.
5. Sullivan S, Kreling D, Hazlet TH. Non-compliance with medication regimens and subsequent hospitalizations: A literature analysis and cost of hospitalization estimate. J Res Pharmac Econom 1990;2:19-33.
6. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997;102:43-9.
7. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-16.
8. Lombas C, Hakim C, Zanchetta JR. Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 2001;15(Abstract M406):S529.
9. Bard R, Goette S, Hadji P, et al. Persistence and compliance with daily and weekly-administered bisphosphonates for osteoporosis treatment in Germany. Osteoporos Int 2005;4:S45.
10. Cramer JA, Amonkar MM, Hebborn A, et al. Does dosing regimen impact persistence with bisphosphonates therapy among postmenopausal osteoporotic women? J Bone Miner Res 2004;19:S448.
11. Recker RR, Gallagher R, Amonkar M, et al. Medication persistence is better with weekly bisphosphonates, but it remains suboptimal. J Bone Miner Res 2004;19:S172.
12. Sebaldt RJ, Shane LG, Pham BZ, et al. Longer-term effectiveness outcomes of non-compliance and non-persistence with daily-regimen bisphosphonates therapy in patients with osteoporosis treated in tertiary specialist care. Osteoporos Int 2004;15:S107.
13. Eastell R, Garnero P, Vrijens L, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: The impact study. Calcif Tissue Int 2003;72 (Abstract P-297).
14. McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-87.
15. Caro JJ, Ishak KJ, Huybrechts KF, et al. Clinical and economic impact of adherence to osteoporosis medication. Osteoporos Int 2003;14:S2.